New data suggest that incidence and prevalence of inflammatory bowel diseases [IBD] are
still increasing worldwide, and approximately 0.2% of the European population suffer from …

Abstract Purpose of Review Once thought a disease of Western civilizations, the
inflammatory bowel diseases (IBD) impose a global burden, now penetrating populations in …

Background & Aims The risk of infection associated with tumor necrosis factor antagonists
(anti-TNF) and thiopurines (combination therapy) is uncertain. We assessed the risk of …

Importance An increased risk of lymphoma has been reported among patients receiving
thiopurines for inflammatory bowel disease (IBD). The risk of lymphoma associated with anti …

Background Real‐world data quantifying the costs of increasing use of biologics in
inflammatory bowel disease (IBD) are unknown. Aim To determine the outpatient IBD drug …

Background There is no head‐to‐head trial comparing ustekinumab and vedolizumab in
patients with Crohn's disease (CD) refractory to anti‐tumour necrosis factor (anti‐TNF). Aim …

Background The magnitude and drivers of the risk of serious viral infections in Inflammatory
Bowel diseases (IBD) are unclear. Objective The objective of this study was to assess the …

Objective Magnitude and independent drivers of the risk of acute arterial events in IBD are
still unclear. We addressed this question in patients with IBD compared with the general …

Abstract Background and Aims The combination of infliximab and azathioprine is more
efficacious than either therapy alone for Crohn's disease [CD] and ulcerative colitis [UC] …

Introduction This study describes the epidemiological, clinical, patient-reported and
economic burden of inflammatory bowel disease (IBD), including Crohn's disease (CD) and …